Aims: The aims of this study were to assess glycemic control, weight loss, and durability of glycemic control in patients initiated on canagliflozin (CANA) versus sitagliptin (SITA). Methods: Adults with type II diabetes mellitus initiated on CANA or SITA (index date) were identified from IQVIA™ Real-World Data Electronic Medical Records – US database (03/29/2012–04/30/2016). Inverse probability of treatment weighting accounted for baseline differences between cohorts. Outcomes were compared using weighted Cox regression and Kaplan-Meier curves and included time to reaching HbA1c thresholds (<7%[53 mmol/mol], <8%[64 mmol/mol], <9%[75 mmol/mol]), weight loss ≥5%, failure to maintain HbA1c below threshold, new antihyperglycemic (AHA) prescription, and failure to maintain HbA1c/new AHA prescription. Results: Weighted cohorts were well balanced (N CANA = 14,542; N SITA = 15,151). CANA patients were 12–15% more likely to reach the HbA1c thresholds, 47% more likely to lose ≥5% of body weight, 31% less likely to have a new AHA prescription, 10–15% less likely to fail to maintain HbA1c, and 13–26% less likely to fail to maintain HbA1c or have a new AHA, versus SITA patients. Conclusions: CANA patients were more likely to reach HbA1c and weight loss thresholds and maintain HbA1c below threshold versus SITA patients, while being less likely to have a prescription for a new AHA, suggesting more durable glycemic control with CANA.
CITATION STYLE
Wysham, C. H., Lefebvre, P., Pilon, D., Lafeuille, M. H., Emond, B., Kamstra, R., … Ingham, M. (2019). An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. Journal of Diabetes and Its Complications, 33(2), 140–147. https://doi.org/10.1016/j.jdiacomp.2018.10.016
Mendeley helps you to discover research relevant for your work.